SCHEMBL21471172

SCHEMBL21471172

C=C(NC(C)C(=C)C(C)(C)C)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24454146 0.82
SCHEMBL24503351 0.77
SCHEMBL17919400 0.73
SCHEMBL21515204 0.73
SCHEMBL22872320 0.73
SCHEMBL22096299 0.72
SCHEMBL18806874 0.72
SCHEMBL26818797 0.70 TDP1 (0.35)
SCHEMBL21534069 0.70 SLC6A3 (0.34)
SCHEMBL1904763 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11793880-B2 Conjugates of quaternized tubulysin compounds SEAGEN INC. (US) 2023-10-24 US disclosed
US-11638762-B2 Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors SEAGEN INC. (US) 2023-05-02 US disclosed
US-11116847-B2 Methylene carbamate linkers for use with targeted-drug conjugates SEAGEN INC. (US) 2021-09-14 US disclosed
US-20190314519-A1 TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS SEATTLE GENETICS, INC. (US) 2019-10-17 US disclosed